Best practice

Industry shift toward systematic access planning during R&D

More pharmaceutical companies are mainstreaming and integrating access planning into their R&D pipelines.

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |